Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus lenalidomide for Castleman disease
ChiCTR2100048364Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab and lenalidomide in Castleman disease (CD), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Overall response rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
rituximablenalidomide
03
Conditions
Castleman disease (CD)
Beyond the preview
Go deeper on ChiCTR2100048364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048364.